[Molecular pathologic KRAS mutation analysis. A prerequisite of effective antibody treatment for metastasized colorectal cancer].
Dietel
M
M
Institut für Pathologie, Charité - Universitätsmedizin Berlin,Campus Mitte, Charitéplatz 1, 10117, Berlin, Deutschland. manfred.dietel@charite.de
Tannapfel
A
A
Baretton
G
G
Kreipe
H
H
Kloor
M
M
Gabbert
H
H
Kirchner
T
T
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D004252:DNA Mutational Analysis; D006801:Humans; D009367:Neoplasm Staging; D000077544:Panitumumab; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D016283:Proto-Oncogene Proteins p21(ras); D016896:Treatment Outcome; D018631:ras Proteins / Q000235:genetics*
D000911:Antibodies, Monoclonal; C117307:KRAS protein, human; D011518:Proto-Oncogene Proteins; D000077544:Panitumumab; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins